Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-TD-nsIL12 Combined With PD-1 Inhibitor in Recurrent High-grade Glioma
NCT07472790Phase 1Not yet recruiting
- Sponsor
- Beijing Bio-Targeting Therapeutics
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad-TD-nsIL12 in glioma, sponsored by Beijing Bio-Targeting Therapeutics. Primary endpoint: Evaluation of the efficacy of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors at 12 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Ad-TD-nsIL12
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07472790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472790.